Drug Profile
GB 5005
Alternative Names: Anti-CD19 CAR-T cells - Shanghai Genechem; Anti-CD19 chimeric antigen receptor T cell therapy - Shanghai Genechem; GB-5005Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Shanghai Genechem
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Leukaemia
- No development reported B-cell lymphoma; Non-Hodgkin's lymphoma
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-0 development in Non-Hodgkin's-lymphoma(Late-stage disease, Second-line therapy or greater) in China (Parenteral, Injection)
- 28 Nov 2021 No recent reports of development identified for clinical-Phase-Unknown development in B-cell lymphoma(Second-line therapy or greater) in China (Parenteral)
- 11 Dec 2020 Shanghai Genechem plans a phase 0 trial for B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) in January 2021 (ChiCTR2000035631)